PRNewsWire
12 Jun 2026, 07:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The Phase 3 CLL14 trial demonstrated that venetoclax plus obinutuzumab significantly doubled median progression-free survival (6.4 years vs 3.2 years) compared to the control group. — Superior long-term efficacy in a primary endpoint strengthens the competitive position and market share potential for Venclexta in first-line CLL.
+0.60The nine-year analysis showed a median time to next treatment (TTNT) of 7.6 years for the venetoclax-based combination. — High durability of response supports a strong value proposition for clinicians and payers, potentially increasing adoption rates.
+0.40The treatment regimen provided these outcomes using a fixed-duration therapy of 12 months. — Fixed-duration therapy is highly attractive to patients compared to continuous treatment, enhancing the drug's commercial appeal.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company announced positive nine-year Phase 3 trial results demonstrating superior progression-free survival and enduring efficacy for its drug Venclexta.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
15h ago
